• 1
    Cassidy JT, Petty RE. Juvenile idiopathic arthritis. In: Textbook of Pediatric Rheumatology, 5th edn. eds CassidyJT, PettyRE. Philadelphia, PA: WB Saunders, 2005; 20660.
  • 2
    Mori M, Naruto T, Imagawa T, Murata T, Takei S, Tomiita M, Itoh Y, Fujikawa S, Yokota S. Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod Rheumatol 2009; 19: 111.
  • 3
    McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 18506.
  • 4
    Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 18390.
  • 5
    Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 18326.
  • 6
    Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 4651.
  • 7
    Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 38324.
  • 8
    van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Allaart CF, Bogaartz J, Tiller M, Huizinga TW, Guchelaar HJ. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007; 8: 14150.
  • 9
    Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 276674.
  • 10
    Toffoli G, De Mattia E. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 2008; 9: 1195206.
  • 11
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 3902.
  • 12
    Mori M, Takei S, Imagawa T, Imanaka H, Maeno N, Kurosawa R, Kawano Y, Yokota S. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Mod Rheumatol 2005; 15: 397404.
  • 13
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 9981006.
  • 14
    Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010; 20: 22232.
  • 15
    Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, Sany J, Daurès JP, Combe B. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63: 67580.
  • 16
    Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TW, Guchelaar HJ. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. : Pharmacogenetics Collaborative Research Group. Arthritis Rheum 2007; 56: 176575.
  • 17
    International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 78996.
  • 18
    Petty RE, Cassidy JT. Polyarthritis. In: Textbook of Pediatric Rheumatology, 5th edn. eds CassidyJT, PettyRE. Philadelphia, PA: WB Saunders, 2005; 26173.
  • 19
    Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. predictors of outcome in juvenile arthritis. Rheumatology 2005; 44: 10027.
  • 20
    Yokota S, Mori M, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, Takei S. Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Pediatric Rheumatology Association of Japan. Mod Rheumatol 2010; 20: 10713.